肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

RET突变有没有很好疗效的药物？

2021-07-30 MedSci原创 MedSci原创

肺癌靶向治疗
关注

RET突变有没有很好疗效的药物？-第一个问题

《梅斯直播课：肺癌诊疗训练营——2021肺癌靶向治疗进展》

回答问题1：RET突变有没有很好疗效的药物？

 

欢迎点赞、评论、分享

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1214136, encodeId=efa6121413655, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7c76521893, createdName=ms9000002073459093, createdTime=Mon Apr 25 15:29:53 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913953, encodeId=d089191395359, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Tue Oct 05 18:46:29 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033064, encodeId=6d4e103306444, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Jul 30 16:46:29 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2022-04-25 ms9000002073459093

    学到了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1214136, encodeId=efa6121413655, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7c76521893, createdName=ms9000002073459093, createdTime=Mon Apr 25 15:29:53 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913953, encodeId=d089191395359, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Tue Oct 05 18:46:29 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033064, encodeId=6d4e103306444, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Jul 30 16:46:29 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2021-10-05 ysjykql

    #RET#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1214136, encodeId=efa6121413655, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7c76521893, createdName=ms9000002073459093, createdTime=Mon Apr 25 15:29:53 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913953, encodeId=d089191395359, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Tue Oct 05 18:46:29 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033064, encodeId=6d4e103306444, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Jul 30 16:46:29 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2021-07-30 内科新手

    谢谢梅斯提供这么好的信息，学到很多

    0

相关资讯

今晚直播：60分钟解读肺癌免疫治疗新近进展

👉 30篇肺癌最新指南报名即得，前200位可申领肿瘤专业纸质书1本

肺癌靶向治疗的现状和发展趋势 —— 精细、联合、克服耐药和脑转移

近年来，肺癌的靶向治疗发展迅速，对于EGFR突变阳性非小细胞肺癌（NSCLC）患者的一线治疗选择以及耐药后的治疗策略，同样令人关注。

拓展阅读

非小细胞肺癌及甲状腺癌治疗传喜讯：Selpercatinib的新药申请获得优先审查

礼来制药公司今日宣布，美国FDA已批准对Selpercatinib（LOXO-292）的新药申请（NDA）进行优先审查，以治疗晚期RET融合阳性非小细胞肺癌（NSCLC）、RET突变型甲状腺髓样癌（MTC）和RET融合阳性甲状腺癌。

RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始

礼来公司近日宣布，selpercatinib（也称为LOXO-292）治疗RET突变型甲状腺髓样癌（MTC）的LIBRETTO-531临床试验（NCT04211337）已开始。